Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

NanoRepro gives revenue guidance: to rise from around €18m in 2026 to €40m in 2030

The board of NanoRepro expects consolidated group revenue of around €18m for 2026, which would be about 12.5% growth versus 2025 (around €16m). Revenue is forecast to increase organically to about €28m by 2028, and management is targeting roughly €40m by 2030 through organic growth and targeted acquisitions. The plan is based on scaling existing brands, consolidating central functions, and expanding margin-strong business areas. » Mais em de.investing.com
NanoRepro: supervisory board member Stiller buys 2,688 shares at €1.86

Dr. Olaf Stiller, a member of NanoRepro’s supervisory board, reported on 18 August 2026 that he purchased 2,688 shares on 17 August 2026 at €1.86 each. Previously, on 31 July 2026 Stiller had bought 5,262 shares at €1.90 each. The stock showed little movement in trading; market capitalization €26.28 million, free float 13,903,603 shares. » Mais em finanzen.net
NanoRepro board member Jüngst acquires 5,435 shares

On 29 May 2026 Lisa Jüngst bought 5,435 NanoRepro shares at €1.84 each; the transaction was reported on 1 June 2026. The stock showed only slight price movement in FSE trading and closed around €1.73–1.74. Previously, additional purchases by Jüngst of 6,984 shares at €1.84 each had already been recorded. » Mais em finanzen.net

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2023, NanoRepro já distribuiu € 0,15 em dividendos. A última distribuição ocorreu em junho de 2023.

Dados financeiros da empresa

No último trimestre, NanoRepro registou receitas de € 1,91 mi e um ganho líquido de -€ 1,14 mi

(EUR)	dezembro de 2025	YoY
Receitas	1,91 mi	-
Ganho bruto	224,2 mil	-
Ganho líquido	-1,14 mi	-
EBITDA	-1,28 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 22,45 mi
Número de ações	12,61 mi
Máximo/mínimo de 52 semanas	€ 2,40 - € 1,31
Dividendos	Não
Beta	0,52
PER (PE Ratio)	-11,30
PEG (PEG Ratio)	3,16
P/VC (PB Ratio)	0,62
P/V (PS Ratio)	5,18

Perfil da empresa

Die NanoRepro AG entwickelt, produziert und vertreibt in Deutschland und international diagnostische Schnelltests und Nahrungsergänzungsmittel für den privaten und professionellen Gebrauch. Das Unternehmen bietet Produkte in den Bereichen Familienplanung und Krankheitserkennung sowie Nahrungsmittelunverträglichkeiten, Allergien und Infektionskrankheiten an. Das Unternehmen bietet diagnostische Schnelltests an, darunter Produkte für die Bereiche Allergie, Familienplanung und Gesundheitsvorsorge; Point-of-Care-Tests für Krankenhäuser und Arztpraxen zum Nachweis von HIV, humanem kardialem Troponin I, D-Dimer, Streptokokken-Antigen, Influenza-Typ-A- und -B-Antigenen und Mikroalbumin; immunchromatographische Lateral-Flow-Tests für den diagnostischen Nachweis von Biomarkern sowie einen SARS-CoV-2-Antikörper-Schnelltest und einen Corona-Antigen-Schnelltest. Es bietet auch Nahrungsergänzungsmittel für Männer und Frauen über Online-Shops sowie über Apotheken an. Der Hauptsitz des Unternehmens befindet sich in Marburg, Deutschland.

Nome	NanoRepro
CEO	Lisa Jungst
Sede	Marburg, he Alemanha
Site	nano.ag
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	22/10/2009
Colaboradores	22